AMLXHealthcare · Drug Manufacturers - Specialty & GenericThe 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +9.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Amylyx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Amylyx Pharmaceuticals, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on AMLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +9.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | Mizuho | Maintains | Outperform | $21 → $24 |
| 25 June 2026 | Guggenheim | Maintains | Buy | $30 → $40 |
| 25 June 2026 | Guggenheim | Maintains | Buy | — |
| 28 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 25 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2026 | Stifel | Initiates | Buy | — |
| 20 Feb 2026 | B of A Securities | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Oct 2025 | Citigroup | Maintains | Buy | — |
| 16 Oct 2025 | Baird | Maintains | Outperform | — |
| 3 Oct 2025 | B of A Securities | Maintains | Buy | — |
| 16 Sept 2025 | Goldman Sachs | Maintains | Buy | — |
| 15 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 28 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 10 July 2025 | Goldman Sachs | Reinstates | Buy | $10 |
| 24 June 2025 | Guggenheim | Initiates | Buy | — |
| 17 June 2025 | Citigroup | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 12% of US stocks
Cheaper than 86% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMLX appears on the weeks it earns a place.
Amylyx Pharmaceuticals announced it will report its second quarter 2026 financial results on August 6, 2026.
Why it matters — An upcoming earnings report provides AMLX watchers with an update on the company's financial performance and operational progress.
The 11 Wall Street analysts covering Amylyx Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $19 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Amylyx Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Amylyx Pharmaceuticals, Inc. 60 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Amylyx Pharmaceuticals, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +9.1% from the last close, and Ticker Nerd's factor model ranks Amylyx Pharmaceuticals, Inc. 60 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amylyx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $40 over the next 12 months.
Amylyx Pharmaceuticals, Inc. returned +161.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions.
The most recent item we track (Business Wire, 3 Aug 2026): "Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026". Amylyx Pharmaceuticals announced it will report its second quarter 2026 financial results on August 6, 2026.
Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol under investigation for Wolfram syndrome; AMX0114 in Phase 1 for amyotrophic lateral sclerosis; and AMX0318, a long-acting GLP-1 receptor antagonist candidate for post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals targets unmet needs in conditions like progressive supranuclear palsy, ALS, and endocrine disorders through clinical trials emphasizing safety, tolerability, and efficacy data. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company operates globally with subsidiaries supporting its research and development efforts in these critical therapeutic areas.
CEO Mr. Joshua B. Cohen · 136 employees · United States · https://amylyx.com